FACS results of HEL cells and 2 primary leukemias, untreated or treated with pathway-specific inhibitors, the external VEGF blocker Ab 4.6.1 or the internal KDR inhibitor, and stained against phosphorylated Erk 1/2 or AKT
Cell line . | Treatment . | P-ERK, % . | P-AKT, % . |
|---|---|---|---|
| HEL | |||
| Untreated | 43.72 | 31.22 | |
| KDRi | 24.22 | 12.50 | |
| 4.6.1 | 42.00 | 30.94 | |
| U0126 | 12.78 | ND | |
| Ly294002 | ND | 10.18 | |
| AML no. 1 | |||
| Untreated | 51.12 | 15.09 | |
| KDRi | 35.78 | 0 | |
| 4.6.1 | 52.40 | 16.07 | |
| U0126 | 20.17 | ND | |
| Ly294002 | ND | 0 | |
| AML no. 3 | |||
| Untreated | 32.00 | 21.00 | |
| KDRi | 18.99 | 4.50 | |
| 4.6.1 | 34.00 | 22.08 | |
| U0126 | 2.26 | ND | |
| Ly294002 | ND | 7.00 |
Cell line . | Treatment . | P-ERK, % . | P-AKT, % . |
|---|---|---|---|
| HEL | |||
| Untreated | 43.72 | 31.22 | |
| KDRi | 24.22 | 12.50 | |
| 4.6.1 | 42.00 | 30.94 | |
| U0126 | 12.78 | ND | |
| Ly294002 | ND | 10.18 | |
| AML no. 1 | |||
| Untreated | 51.12 | 15.09 | |
| KDRi | 35.78 | 0 | |
| 4.6.1 | 52.40 | 16.07 | |
| U0126 | 20.17 | ND | |
| Ly294002 | ND | 0 | |
| AML no. 3 | |||
| Untreated | 32.00 | 21.00 | |
| KDRi | 18.99 | 4.50 | |
| 4.6.1 | 34.00 | 22.08 | |
| U0126 | 2.26 | ND | |
| Ly294002 | ND | 7.00 |
Note the effect of the internal KDR inhibitor at reducing the percentage of cells with phosphorylated Erk 1/2 or AKT, whereas the external VEGF blocker has little effect. This result is consistent with the Western blot results (in the case of the HEL cell line), and in the different leukemias analyzed. The results shown are representative of 3 independent experiments.
ND indicates not detected.